Printer Friendly

Spark Therapeutics price target lowered to $77 from $91 at Mizuho.

Mizuho analyst Difei Yang lowered her price target for Spark Therapeutics (ONCE) to $77 after the company provided an update on the SPK-8011 program for hemophilia A. While the latest data appears "somewhat mixed" with two out of the seven patients not maintaining Factor VIII level of at least 12%, Spark offered a reasonable explanation and proposal to address the issue in the upcoming Phase III trial that is scheduled to begin in Q4, Yang tells investors in a research note. The analyst finds it premature to draw the conclusion that SPK-8011 is inferior to the competing product from BioMarin (BMRN). Yang removed a takeover premium for Spark in her new price target but keeps a Buy rating on the shares.

COPYRIGHT 2018 The Fly
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:The Fly
Date:Aug 8, 2018
Previous Article:United Therapeutics says FREEDOM-EV study of Orenitram met primary endpoint.
Next Article:U.S. to impose tariffs on additional $16B in Chinese imports, WSJ reports.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters